DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
NEWARK, Calif., March 06, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of March.
30th Annual ROTH Capital Partners Conference
Date: Tuesday, March 13, 2018
Time: 12:30 p.m. PDT/ 3:30 p.m. EDT
Location: Dana Point, CaliforniaOppenheimer 27th Annual Healthcare Conference
Date: Tuesday, March 20, 2018
Time: 1:35 p.m. EDT
Location: New York, New York
The fireside chats will be webcast live and may be accessed via the Investor Relations’ page of the Depomed website at www.depomed.com. A recording of these events will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its neurology and pain franchises and its emerging specialty/orphan franchise is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
Investor and Media Contacts:
Christopher Keenan
VP, Investor Relations and Corporate Communications
510-744-8000
[email protected]
Dan Peisert
VP, Business Development
[email protected]
